Research
Rituximab not superior to azathioprine for EGPA remission maintenance
Nature ·
The Brief
- Headline reports that rituximab was not superior to azathioprine for maintaining remission in EGPA.
- No summary is available in the source, so trial design and results are not described.
Why it matters
Clinicians choosing maintenance therapy for eosinophilic granulomatosis with polyangiitis (EGPA) may find the comparison relevant, though the available source gives no further detail.
Who’s affected
- clinicians treating eosinophilic granulomatosis with polyangiitis
- patients with EGPA
- #egpa
- #rituximab
- #azathioprine
- #vasculitis
- #rheumatology